SCHEMBL23747381

SCHEMBL23747381

COc1ccc(C(C)=O)c(-c2cc(Cl)ccc2OC)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.54
KMT2A Q03164 5/20 0.54
POLB P06746 3/20 0.52
ALDH1A1 P00352 5/20 0.52
HPGD P15428 4/20 0.50
CYP3A4 P08684 1/20 0.50
MAPK1 P28482 1/20 0.50
MEN1 O00255 4/20 0.48
ABCG2 Q9UNQ0 1/20 0.47
RAB9A P51151 1/20 0.47
KDM4E B2RXH2 1/20 0.46
TP53 P04637 1/20 0.46
GLA P06280 1/20 0.46
HSD17B10 Q99714 1/20 0.46
PNLIP P16233 1/20 0.46
NPC1 O15118 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
AHR P35869 1/20 0.46
LMNA P02545 2/20 0.46
AKR1C3 P42330 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20194493 0.86 ALDH1A1 (0.52) MAPTKMT2APOLBALDH1A1HPGD
SCHEMBL14610550 0.81 HDAC4 (0.60) MAPTKMT2APOLBALDH1A1HPGD
SCHEMBL5631648 0.81 MAPT (0.55) MAPTKMT2APOLBALDH1A1HPGD
SCHEMBL364764 0.80 ALDH1A1 (0.65) MAPTKMT2APOLBALDH1A1HPGD
SCHEMBL14439661 0.79 ALDH1A1 (0.48) MAPTKMT2AALDH1A1MAPK1MEN1
SCHEMBL14398936 0.79 AKR1C3 (0.54) MAPTKMT2APOLBALDH1A1HPGD
SCHEMBL19945739 0.78 ALDH1A1 (0.47) KMT2APOLBALDH1A1MEN1NPC1
SCHEMBL19945811 0.77 MEN1 (0.47) KMT2APOLBALDH1A1MEN1NPC1
SCHEMBL29479275 0.77 MEN1 (0.47) KMT2APOLBALDH1A1MEN1NPC1
SCHEMBL498726 0.76 FLT1 (0.55) MAPTKMT2APOLBALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2023-01-10 US disclosed
US-20210244717-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT Valo Health, LLC 2021-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11547701-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NQO1 MAPT 268/4885KMT2A 908/4885POLB 1931/4885
US-20210244717-A1 NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT NAMPT, NNMT, NQO1 MAPT 519/4885KMT2A 1615/4885POLB 2930/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.